Patent 11261151 was granted and assigned to Atossa Therapeutics, Inc. on March, 2022 by the United States Patent and Trademark Office.
The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifen, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.